Update on the Treatment of Metastatic Urothelial Carcinoma
Joint Authors
Bukhari, Nedal
Azam, Faisal
Al-Shamsi, Humaid O.
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-06-06
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Medicine
Information Technology and Computer Science
Abstract EN
Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC).
Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years.
Clinical trials are currently ongoing to determine how best to use and sequence these treatments.
In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy.
This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.
American Psychological Association (APA)
Bukhari, Nedal& Al-Shamsi, Humaid O.& Azam, Faisal. 2018. Update on the Treatment of Metastatic Urothelial Carcinoma. The Scientific World Journal،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1215633
Modern Language Association (MLA)
Bukhari, Nedal…[et al.]. Update on the Treatment of Metastatic Urothelial Carcinoma. The Scientific World Journal No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1215633
American Medical Association (AMA)
Bukhari, Nedal& Al-Shamsi, Humaid O.& Azam, Faisal. Update on the Treatment of Metastatic Urothelial Carcinoma. The Scientific World Journal. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1215633
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1215633